Integrated sequencing strategies have provided a broader understanding of the genomic
landscape and molecular classifications of multiple cancer types and have identified various …

Epidermal growth factor receptor (EGFR) has fundamental roles in normal physiology and
cancer, making it a rational target for cancer therapy. Surprisingly, however, inhibitors that …

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor
antagonist (beta-blocker), with a range of actions which are of interest in an oncological …

Drug delivery to tumors is limited by several factors, including drug permeability of the target
cell plasma membrane. Ultrasound in combination with microbubbles (USMB) is a promising …

Abstract Neuropilin-2 (NRP2) is a non-tyrosine kinase receptor frequently overexpressed in
various malignancies, where it has been implicated in promoting many protumorigenic …

Abstract Trastuzumab emtansine (T-DM1) is an antibody drug conjugate (ADC) that was
recently approved for the treatment of HER-2-positive metastatic breast cancer. The drug …

The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1,
Kadcyla) has been approved by the US FDA to treat human epidermal growth factor receptor …

Ligand‐independent epidermal growth factor receptor (EGFR) endocytosis is inducible by a
variety of stress conditions converging upon p38 kinase. A less known pathway involves …

Rab35 is a small GTPase that is involved in many cellular processes, including membrane
trafficking, cell polarity, lipid homeostasis, immunity, phagocytosis and cytokinesis. Recent …

Epithelial cells can acquire invasive and tumorigenic capabilities through epithelial–
mesenchymal-transition (EMT). The glycan-binding protein galectin-8 (Gal-8) activates …